# BPC-157 Dosage Research Context — Preclinical Doses, Routes, and Pharmacokinetics > BPC-157 preclinical dosing data: rodent study dose ranges (10 pg/kg to 20 mg/kg), administration routes with bioavailability, plasma half-life, and human pilot dosing context. Research context only. ## Pharmacokinetics A 2022 formal PK study in Sprague-Dawley rats and beagle dogs documented BPC-157 pharmacokinetics across IV and intramuscular routes [11]: - **Elimination half-life:** Less than 30 minutes in both species after IV and IM administration. - **Cmax timing:** Peak plasma concentration at 3–9 minutes post-IM injection. - **IM bioavailability:** 14–19% in rats; 45–51% in beagle dogs. - **Dose-proportionality:** Linear dose-proportional kinetics confirmed at IV doses of 20 μg/kg in rats and 6 μg/kg in dogs. - **Tissue distribution:** Highest concentrations post-IV in kidney, liver, and stomach. - **Excretion route:** Primarily via urine and bile through rapid peptide fragmentation. Despite the short systemic half-life, in vivo efficacy in tissue-repair models persists well beyond plasma clearance — possibly via rapid receptor engagement triggering downstream gene expression cascades. Gastric stability enables per-oral delivery without a protective formulation or carrier. ## Research Doses by Study Type The following dose ranges appear in the peer-reviewed preclinical literature. These are study-context parameters; they are not dosing recommendations for any purpose. **Intraperitoneal injection (rodent models — most common route):** Standard dose ladder: 10 μg/kg, 10 ng/kg, 10 pg/kg. Multiple studies show efficacy across this picogram-to-microgram range. **Oral administration (drinking water or gavage):** 10 μg/kg/day and 10 ng/kg/day in drinking water (approximately 0.16 μg/mL, 12 mL/rat/day). Oral per-oral delivery produced results comparable to IP in multiple studies. **Topical cream:** 1 μg/g, applied daily. **Subcutaneous injection:** 10 μg/kg and 10 ng/kg in intra-abdominal hypertension reperfusion model [12]. **Intramuscular injection (dog PK study):** 6, 30, 150 μg/kg in formal PK dose-response characterization [11]. **Local injection:** 10 μg/kg directly into a 0.8 cm rabbit radial bone defect [6]. **High-dose toxicology reference:** No toxic dose established up to 20 mg/kg in rats and 10 mg/kg in dogs [20]. **Human pilot doses (not preclinical):** - Intra-articular knee injection: dose not specified [16]. - Intravesical IC injection: 10 mg single dose [15]. - IV infusion safety pilot: 10 mg on Day 1, 20 mg on Day 2, infused over 1 hour each [14]. ## Administration Routes in Research Context Nine distinct routes appear across the published literature: 1. **Intraperitoneal (IP)** — Standard rodent research route; no equivalent in human clinical practice. 2. **Subcutaneous (SC)** — Used in hypertension-reperfusion study [12]. 3. **Intramuscular (IM)** — Formal PK characterization; bioavailability 14–19% (rat), 45–51% (dog) [11]. 4. **Intravenous (IV)** — PK studies and the 2025 human safety pilot [11, 14]. 5. **Oral gavage** — Rodent research via gavage syringe. 6. **Oral in drinking water** — Ad libitum per-oral; consistent efficacy with IP in matched studies [3, 18]. 7. **Topical cream (1 μg/g)** — Direct application to wound or injured tissue surface [3, 4, 5]. 8. **Local injection into injury site** — Direct injection into bone defect in the rabbit model [6]. 9. **Intravesical instillation** — 10 mg injected directly into the bladder; used in the human IC pilot [15]. ## Half-Life and Sustained Efficacy: A Note on PK-PD Dissociation The plasma elimination half-life of less than 30 minutes raises a pharmacologically interesting question: how does a peptide with a sub-30-minute half-life produce tissue repair effects measured at day 14, day 28, and day 90 in published studies? The preclinical literature points to rapid receptor engagement — particularly via the VEGFR2 pathway — triggering downstream transcriptional cascades (VEGF upregulation, CD34 expression, FAK-paxillin activation) that continue well after BPC-157 has been cleared systemically [7, 17]. The 2025 Pharmaceuticals review [20] identifies the short half-life as a key formulation consideration — a factor driving the ten active patents documented in that review. ## References [3] Cerovecki T et al. Journal of Orthopaedic Research. 2010. DOI: 10.1002/jor.21107 [4] Seiwerth S et al. Frontiers in Pharmacology. 2021. DOI: 10.3389/fphar.2021.627533 [5] Novinscak T et al. Surgery Today. 2008. DOI: 10.1007/s00595-007-3706-2 [6] Sebecic B et al. Bone. 1999. DOI: 10.1016/s8756-3282(98)00180-x [7] Brcic L et al. Journal of Physiology and Pharmacology. 2009. PMID: 20388964 [11] He L et al. Frontiers in Pharmacology. 2022;13:1026182. DOI: 10.3389/fphar.2022.1026182 [12] Tepes M et al. Pharmaceuticals (Basel). 2023;16(11):1554. DOI: 10.3390/ph16111554 [14] Lee E, Burgess K. Alternative Therapies in Health and Medicine. 2025. PMID: 40131143 [15] Lee E, Walker C, Ayadi B. Alternative Therapies in Health and Medicine. 2024. [16] Lee E, Padgett B. Alternative Therapies in Health and Medicine. 2021. PMID: 33609460 [17] Vasireddi N et al. HSS Journal. 2025. DOI: 10.1177/15563316251355551 [18] Matek D et al. Pharmaceutics. 2025;17(1):119. DOI: 10.3390/pharmaceutics17010119 [20] Jozwiak M et al. Pharmaceuticals (Basel). 2025;18(2):185. DOI: 10.3390/ph18020185 --- For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.